Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Defensive Interval Ratio
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Defensive Interval Ratio of 12408 days as of June 2026. Defensive assets of $221.84 Million (cash $-, short-term investments $221.84 Million, receivables $-) cover 12408 days of daily cash needs of $17.88K/day.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Contineum Therapeutics, Inc. Class A Common Stock Defensive Interval Ratio (2021–2025)
This chart shows how Contineum Therapeutics, Inc. Class A Common Stock's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of June 2026, the ratio stands at 12408 days, meaning defensive assets of $221.84 Million can fund 12408 days of operations without new revenue. For the complete balance sheet picture, see Contineum Therapeutics, Inc. Class A Com balance sheet assets.
Annual Defensive Interval Ratio for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below presents the year-by-year Defensive Interval Ratio for Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. See CTNM current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 7016 days | $187.29 Million | $26.70K/day | $- | $187.29 Million | ▲ +326 days |
| 2024 | 6690 days | $182.82 Million | $27.33K/day | $- | $182.82 Million | ▼ -609 days |
| 2023 | 7299 days | $109.66 Million | $15.02K/day | $- | $109.66 Million | ▲ +5284 days |
| 2022 | 2015 days | $41.67 Million | $20.68K/day | $- | $41.67 Million | ▼ -4381 days |
| 2021 | 6395 days | $64.37 Million | $10.07K/day | $- | $64.37 Million | — |